In 2025 a proposed module combined observations collected over twenty-one days under one specified storage condition. The commercial proposition described a shelf-life answer, and its annual licence-revenue forecast was ₹4.6 crore. The available observations could support examination of a bounded trend in that demonstration. They did not, on their own, establish the broader duration promise implied by the proposed product. Other conditions, endpoints and professional assessment had not been addressed by the software account.
The sales and product teams wanted to preserve the higher-value proposition because customers were asking a practical question about duration. I did not dispute that demand. I asked what evidence the feature would need to answer it responsibly and which party would hold the necessary scientific responsibility. Peter Qezvomi would not endorse the general claim from the limited study. CEO Anita Qevrasi asked us to present the commercial consequences of narrowing the feature instead of leaving the caveat to implementation after an attractive investment case had been approved.
We withdrew the general shelf-life proposition and retained a trend-view workbench whose stated scope matched the observations. The revised annual licence-revenue forecast was ₹1.8 crore, still a forecast rather than contracted or realised revenue. We preserved ₹37 lakh already spent on discovery and approved a separate ₹1.2 crore redesign programme, which remains unfinished in this fictional account. No safety certification or universal duration was attached to the workbench. Its purpose was to help qualified researchers inspect the recorded conditions and observations, not to replace their assessment with a date displayed by software.
The decision gave up part of the proposed commercial story and required a different sales explanation. The ₹2.8 crore reduction between forecasts was not money already lost, while the discovery expense could not be erased by changing the name of the feature. My role was to connect the evidential boundary with the investment paper and product requirements. The CEO and relevant approving bodies retained their authority. The result is deliberately incomplete: a smaller, more defensible proposition with funded work still to do, rather than a claim that caution inevitably produces a superior financial outcome.